Halozyme Therapeutics, Inc.
HALO· Nasdaq
HALOHalozyme Therapeutics, Inc.
Filed Feb 22, 2022 · 10-K · 53 days after period end · 0001159036-22-000014
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $102.00M | $121.70M | $53.67M | $60.23M |
| Net Income | $66.77M | $73.16M | -$34.40M | -$2.13M |
| EPS Diluted | — | $0.50 | -$0.24 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Feb 22, 2022 · 53 d after period end
